The present invention is directed to an apparatus and method of accelerating and/or inhibiting metastasis of cells by subjecting the cells to an electric field. More particularly, the present invention is directed to an apparatus and method for accelerating and/or inhibiting metastasis of cancer cells by applying a time-varying magnetic field to induce eddy currents that promote electrotaxis (galvanotaxis) of cells without the need for chemokines or glucose.
In a preferred embodiment of the present invention, a time-varying magnetic field from an electromagnetic (EM) coil is used to induce electric fields in a modified version of Corning's Transwell permeable assay. By varying the characteristics of the excitation of the EM coil and the direction of application of the electric field, it is possible to accelerate cell migration as well as inhibit it, in the presence or absence of chemokines. The modified assay provides a novel method to study and quantify metastasis. For example, metastatic cell lines can be compared to each other in these assays by subjecting them to the EM fields and counting the number of cells that migrate across the permeable membrane. Comparisons between cell lines can also be drawn and quantified in the presence of both EM fields and chemokines. Quantification can be accomplished by counting the cells or by digitizing the image and calculating cell coverage areas on the bottom of the membrane. In one embodiment, the EM coil is driven using a function generator using a 20 Vpp, 100 kHz, sawtooth wave with a sharp ˜50 ns drop to generate a rapidly time-varying magnetic field.
In an exemplary embodiment of the present invention, the method is comprised of the steps of:
In one embodiment the waveform applied to the coil is a 20 volts peak to peak, 100 kHz sawtooth waveform with a 50 ns drop off at its trailing edge that induces a rapidly time-varying magnetic field.
It is appreciated that the characteristics of the waveform can be adjusted to control metastasis.
Furthermore, the following additional steps may be taken according to one embodiment of the invention for studying and quantifying the metastatic potential of cell lines:
The foregoing and other features and advantages of the present invention will be apparent from the following more detailed description of the particular embodiments, as illustrated in the accompanying drawings.
The following detailed description of the example embodiments refers to the accompanying figures that form a part thereof. The detailed description provides explanations by way of exemplary embodiments. It is to be understood that other embodiments may be used having mechanical and electrical changes that incorporate the scope of the present invention without departing from the spirit of the invention.
In addition to the features mentioned above, other aspects of the present invention will be readily apparent from the following descriptions of the drawings and exemplary embodiments, wherein like reference numerals across the several views refer to identical or equivalent features, and wherein:
An assay that is commonly used to evaluate the response of cancer cells to chemokines and chemotherapy drugs is Corning's Transwell Permeable Support assay 10. In this assay, inserts 12 with porous membranes 16 at the bottom are placed into standard plate wells as shown in
The system and method of the present invention is used for inducing electric fields in the medium containing cells, for example the Corning's Transwell permeable assay, by applying time-varying magnetic fields. The method uses electromagnetic (EM) induction to induce electric fields and eddy currents in the medium to promote galvanotaxis of cells without the need for chemokines or glucose. This is of significance since cancer cells are known to respond to externally applied electric fields so that they can be distinguished from normal cells. Moreover, metastatic potential of different cancer cells may be quantitatively evaluated by counting the number of cells migrated across the membrane, so that this can form the basis for a new assay.
In one embodiment, a SCP2 cell line cultured in Dulbecco's Modified Eagle Medium (DMEM) without serum with a density of 3.3×106 cells/mL is used. This cell line is a highly metastatic estrogen receptor (negative) breast cancer cell line derived from the MDA-MB-231 cell line. In this embodiment, 150 μL of the medium containing this cell line (˜4.95×104 cells) is pipetted into the upper compartment of a single Transwell permeable insert (equipped with a 6 μm filter) while the lower compartment has 200 μL of the same medium but with no cells. The single plate well with the insert is then placed adjacent to a horizontally oriented electromagnetic (EM) coil (R˜22Ω, L=10 mH) and fixture as shown in
In one embodiment, the EM coil is driven using a function generator using a 20 Vpp, 100 kHz, sawtooth wave with a sharp ˜50 ns drop to generate a rapidly time-varying magnetic field with components Br and Bz. By Faraday's law these temporally varying magnetic fields from the EM coil induce an electric field Eθ in the medium containing the cells due to the small but non-zero electrical conductivity of the medium. Because of the placement of the plate well relative to the coil, this results in a vertically directed electric field across the membrane, but with Eθ decaying radially with increasing distance from the coil. At the driving frequency of 100 kHz, Eθ switches directions back and forth (up and down) across the membrane, but with a non-equal component directed downward or upward depending on the side of the coil.
In addition to implications for hindering metastasis, Corning's Transwell assay can be modified to provide a method to quantify metastasis. For instance, metastatic cell lines can be compared to each other in these assays by subjecting them to the same EM fields and counting the number of cells that migrate across the permeable membrane. The quantification can be accomplished by counting the cells or by digitizing the image and calculating cell coverage areas on the bottom of the membrane. The effects of various drugs and chemokines may also be evaluated in the presence of EM fields so as to decipher the effects of in vivo endogenous electric fields that may adversely affect the therapeutic effects of chemotherapy drugs.
In summary, a time-varying magnetic field from an electromagnetic (EM) coil is used to induce electric fields in a modified version of Corning's Transwell permeable assay. Preliminary in vitro experiments on the highly metastatic SCP2 breast cancer cell lines show that cell migration across the membrane can be significantly increased compared to the control case where no EM field is applied. By varying the characteristics of the excitation of the EM coil, it is possible to accelerate metastasis as well as inhibit it. This degree of control without the use of chemokines suggests a natural means of quantifying the metastatic potential of different cancer cells as well as a natural means of comparing them with the motility of normal cells.
While certain embodiments of the present invention are described in detail above, the scope of the invention is not to be considered limited by such disclosure, and modifications are possible without departing from the spirit of the invention as evidenced by the following claims:
This application is a divisional of U.S. application Ser. No. 14/765,993, filed Aug. 5, 2015, which is a national stage entry of PCT/US14/14779, filed Feb. 5, 2014, which claims priority to U.S. Provisional Application No. 61/760,987 filed on Feb. 5, 2013. Each of which is incorporated by reference as if fully recited herein.
Number | Name | Date | Kind |
---|---|---|---|
6790330 | Gascoyne et al. | Sep 2004 | B2 |
7012100 | Edwards et al. | Mar 2006 | B1 |
7117034 | Kronberg | Oct 2006 | B2 |
7700615 | Edwards et al. | Apr 2010 | B2 |
8019414 | Palti | Sep 2011 | B2 |
20040152067 | Wang et al. | Aug 2004 | A1 |
20060276858 | Palti | Dec 2006 | A1 |
20080299086 | Kanzaki | Dec 2008 | A1 |
20090018613 | Brighton | Jan 2009 | A1 |
20100273258 | Lannutti | Oct 2010 | A1 |
20100298624 | Becker | Nov 2010 | A1 |
20110194979 | Chin et al. | Aug 2011 | A1 |
20120035457 | Subramaniam et al. | Feb 2012 | A1 |
20120064594 | Van Bree | Mar 2012 | A1 |
20130034899 | Takemura | Feb 2013 | A1 |
20160340635 | Kirshner | Nov 2016 | A1 |
20190161722 | Nagatomi | May 2019 | A1 |
Number | Date | Country |
---|---|---|
2011063458 | Jun 2011 | WO |
Entry |
---|
Bullock, A. et al., The Effect of Induced Biphasic Pulsed Currents on Re-Epithelialization of a Novel Wound Healing Model, Bioelectromagnetics vol. 28 No. 1, Jan. 1, 2007, pp. 31-41. |
Djamgoz, M. et al., Directional Movement of Rat Prostate Cancer Cells in Direct-Current Electric Field: Involvement of Voltage-Gated Na+ Channel Activity, Journal of Cell Science 114 (14), 2001, pp. 2697-2705. |
Fraser, S. et al., Voltage-Gated Sodium Channel Expression and Potentiation of Human Breast Cancer Metastasis, Clinical Cancer Research 11, Aug. 1, 2005, pp. 5381-5389. |
Hart, F. et al., Keratinocyte Galvanotaxis in Combined DC and AC Electric Fields Supports an Electromechanical Transduction Sensing Mechanism, Bioelectromagnetics 34, Feb. 2013, pp. 85-94. |
Song, B. et al., Application of Direct Current Electric Fields to Cells and Tissues in Vitro and Modulation of Wound Electric Field in Vivo. Nature Protocols. vol. 2 No. 6., Jun. 2007, pp. 1479-489. |
Sun, et al., Electrotaxis of lung cancer cells in ordered three-dimensional scaffolds, Biomicrofluids 6, 2012. |
Vianale, G. et al., Extremely Low Frequency Electromagnetic Filed Enhances Human Keratinocyte Cell Growth and Decreases Proinflammatory Chemokine Productions. British Journal of Dermatology. vol. 158 No. 6., Jun. 2008, pp. 1189-1196. |
Yan, X. et al., Lung Cancer A549 Cells Migrate Directionally in DC Electric Fields with Polarized and Activated EGFRs, Bioelectromagnetics 30, 2009, pp. 29-35. |
Number | Date | Country | |
---|---|---|---|
20180037882 A1 | Feb 2018 | US |
Number | Date | Country | |
---|---|---|---|
61760987 | Feb 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14765993 | US | |
Child | 15724298 | US |